Three teams of highly respected Alzheimer’s researchers failed to replicate what appeared to be breakthrough results for the treatment of Alzheimer's disease using existing cancer drug Targretin® (brand name Bexarotene).
The original results, presented online Feb. 9, 2012, suggested that the drug bexarotene could rapidly reverse the buildup of beta amyloid plaques (Aβ) — a pathological hallmark of Alzheimer’s disease — in the brains of mice.
Google Search Recommends
+Bob DeMarco , +Alzheimer's Reading Room
To learn more about Alzheimers and Dementia care visit the Alzheimer's Reading Room